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Background: Chemokine receptor CCR7 
promotes survival in mature dendritic cells 
(mDCs). 
Results: Activated AMP-dependent kinase 
(AMPK) induces apoptosis in mDCs. CCR7 uses 
the kinases MEK1/2-ERK1/2 to regulate 
phosphorylation of AMPK on Ser485 and 
consequently its inhibition.  
Conclusion: CCR7 uses a novel MEK1/2-
ERK1/2-AMPK signalling axis to induce 
survival in mDCs. 
Significance: AMPK is a potential target to 
regulate mDC-mediated immune responses. 
 
Abstract  
Chemokine receptor CCR7 directs mature 
dendritic cells (mDCs) to secondary lymph 
nodes (LNs) where these cells regulate the 
activation of T cells. CCR7 also promotes 
survival in mDCs, which is believed to take 
place largely through Akt-dependent 
signalling mechanisms. We have analysed the 
involvement of the AMP-dependent kinase 
(AMPK) in the control of CCR7-dependent 
survival. A pro-apoptotic role for AMPK is 
suggested by the finding that pharmacological 
activators induce apoptosis, whereas 
knocking-down of AMPK with siRNA extends 
mDCs survival. Pharmacological activation of 
AMPK also induces apoptosis of mDCs in the 
LNs. Stimulation of CCR7 leads to inhibition 
of AMPK, through phosphorylation of 
Ser485, which was mediated by Gi/Gbut 
not by Akt or S6K, two kinases that control 
the phosphorylation of AMPK on Ser485 in 
other settings. Using selective 
pharmacological inhibitors, we show that 
CCR7-induced phosphorylation of AMPK on 
Ser485 is mediated by MEK and ERK. 
Coimmunoprecipitation analysis and 
Proximity Ligation Assays (PLA) indicate 
that AMPK associates with ERK, but not 
with MEK. The results suggest that in 
addition to Akt-dependent signalling 
mechanisms, CCR7 can also promote survival 
of mDCs through a novel MEK1/2-ERK1/2-
AMPK signalling axis. The data also suggest 
that AMPK may be a potential target to 
modulate mDC lifespan and the immune 
response. 
 
Mature dendritic cells (mDCs)
2 are potent 
antigen presenting cells that stimulate naïve T 
cells in the lymph nodes (1). It has been shown 
that the longevity of mDCs importantly affects 
the immune response. In this regard, both mice 
depleted of mDCs or that present aberrant long 
lived mDCs, develop autoimmune diseases (2-
6). However, between these two extremes, it is 
observed that the immune response improves as 
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the longevity of the mDCs increases (3,7). The 
aforementioned results suggest that obtaining 
information on the mechanisms that regulate 
mDC survival can be very useful to develop 
strategies to modulate the longevity of these 
cells and improve the immune response.  
Chemokine receptor CCR7 (ligands CCL19 
and CCL21) directs mDCs to the lymph nodes 
(LNs), attracted first by CCL21, which is 
expressed in the lymphatic vessels that lead to 
the LNs, and then by both CCL19 and CCL21, 
which are both expressed by stromal cells in the 
LNs (8,9). Apart from directing the migration of 
mDCs, CCR7 also promotes survival in these 
cells (10-12), although the signalling 
mechanisms that regulate the latter function are 
starting to be defined. Before we showed that 
CCR7-regulated survival in mDCs is mediated 
by the Gi family of G proteins and the kinase 
Akt (10,11). This kinase promotes survival 
through activation of the transcription factor 
NFB and inhibition of several pro-apoptotic 
targets, including the transcription factors 
FOXO1/3 and the kinase GSK3 (10-12).  
AMP-dependent kinase (AMPK) is 
considered a molecular sensor of cellular energy 
status (13,14). Under conditions of low cellular 
energy status, AMPK becomes activated, 
resulting in the stimulation of ATP-producing
 
(catabolic) pathways and the inhibition of ATP-
consuming (anabolic) processes (13,14), which 
together leads to the recovery of the ATP/ADP 
ratio of the cell. Recently, it has emerged that 
AMPK may also promote survival (e.g. (15)) or 
apoptosis (e.g. (16)) depending on the cell type. 
AMPK is activated upon phosphorylation of 
Thr-172, which is located on the activation loop 
of the catalytic -subunit of the kinase (17), and 
it is inhibited by phosphorylation of Ser485/491 
(AMPKα1 on Ser485 and AMPKα2 on Ser491) 
(18-20). Phosphorylation of Ser485/491 blocks 
the activity of AMPK, even when Thr-172 is 
phosphorylated, suggesting that phosphorylation 
of the aforementioned Ser residues exerts a 
dominant inhibitory role on activity of AMPK 
(21). It has been shown that the kinases Akt 
(18,22,23) or S6K (21) can inhibit AMPK by 
directly phosphorylating Ser485/491 in different 
cell types. Herein we have studied whether the 
kinase AMPK plays a role in the regulation of 
the survival of mDCs. We show, first, that 
AMPK can play pro-apoptotic roles in mDCs 
both in vitro and in vivo; second, that the 
stimulation of CCR7 in mDCs leads to a rapid 
inhibition of AMPK through the phosphorylation 
of Ser485, third, that MEK/ERK mediate the 
CCR7-dependent inhibition of AMPK; fourth, 
that ERK, but not MEK, interacts with AMPK. 
Together, the results indicate that CCR7 can 
contribute to extend the survival of mDCs 
through the novel MEK1/2-ERK1/2-AMPK 
signalling axis. The results also suggest that the 
kinase AMPK may be a potential target to 
modulate the immune response. 
 
 
EXPERIMENTAL PROCEDURES 
Reagents and Materials- CCL19, CCL21 and 
TNF were from Peprotech (Rocky Hill, NJ). 
GM-CSF and IL4 were purchased from 
Immunotools. Fluorescent dye CFSE 
(carboxyfluorescein diacetate succinimidyl ester) 
was obtained from Molecular Probes. FLIVO
TM
 
is Val-Ala-Asp(OMe)-fluoromethyl ketone 
(VAD-FMK). Sulforhodamine B (SR)-FLIVO 
(SR, λabs 565 nm; λem >600 nm), a form of 
FLIVO conjugated to Sulforhodamine B, was 
obtained from Immunochemistry Technologies, 
LLC. Z-VAD-FMK was obtained from Enzo 
(Life Sciences). LY294002, Akt1/2 inhibitor, 
Pertussis toxin, Hoechst 33342, Propidium 
iodide and the anti--tubulin antibodies were 
from Sigma. Compound C (24), UO126 and 
PD0325901, ERK activation inhibitor peptide II, 
were from Calbiochem (Nottingham, UK). 
Rapamycin, KU0063794, Gallein, A769662 and 
FR180204 were obtained from Tocris 
Bioscience (Bristol, UK). CAY10561 was from 
Cayman Chemicals (Ann Harbour, MI, USA). 
The anti-Bim antibody was from Affinity 
BioReagents (Golden, Colorado, USA). The 
MEK1, -actin, 4E-BP1, ERK1, ERK2 and the 
anti-AMPK antibodies were from Santa Cruz 
Biotechnology Inc. (Santa Cruz, CA). The anti-
Akt1, the anti Bclxl, the anti-AMPK, the anti- 
TSC2, the anti-mTOR, the anti-phospho-
MEK1/2 (Ser217/221), the anti-phospho-
ERK1/2 (Thr202/Tyr-204 in ERK1, Thr185/Tyr-
187 in ERK2), the anti-phospho-Akt1 (Ser473), 
the anti-phospho-AMPK1 (Ser485), the anti-
phospho-AMPK (Thr172), the anti-phospho-
TSC2 (T1462), the anti-phospho-mTOR (S2448) 
and the anti-phospho-4EBP1 (T37/46), the anti-
phospho-p70-S6K (Thr389), the anti-p70-S6K 
were from Cell Signaling Technology (Beverly, 
MA). The the anti-phospho-acetyl CoA- 
carboxylase (Ser 79) was from Millipore. The 
anti-cleave caspase 3 was form BioOrbyt 
(Cambridge, UK).  
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Mice- C57BL/6 mice (8-10 weeks) were 
maintained in the animal facility at the Centro de 
Investigaciones Biológicas and treated according 
to Animal Care Committee guidelines.  
Purification of murine DCs and labelling of 
the cells with fluorescent cell trackers-Murine 
DCs were purified (97% CD11c
+
) from spleens 
of donor mice using magnetic beads (Miltenyi) 
following the manufacturer’s protocol. DCs used 
in the in vivo studies were labelled for 30 min at 
37°C with 2.5 µM of the fluorescent cell tracker 
probe CFSE in 0.1% BSA in PBS. 
Cells and culture conditions- Human 
peripheral blood mononuclear cells (PBMC) 
were isolated from buffy coats from normal 
donors over a Lymphoprep (Nycomed, Norway). 
Monocytes were purified using anti-CD14 
magnetic beads (Miltenyi) following the 
manufacturer’s protocol and then induced to 
differentiate to DCs by adding GM-CSF and IL4 
for 7 days as indicated before (10,11,25-27). The 
DCs were induced to mature by adding TNF as 
indicated before (10,11,25-27). 
Assays of apoptotic damage in vitro- An 
equal number of live mDCs (determined by 
exclusion on trypan blue staining) were 
incubated in 0.1% BSA or 10% FCS in RPMI in 
the presence or absence of AMPK activators. 
Subsequently the mDCs were harvested and 
plated for 40 min on polyornithine-coated 
coverslips. Apoptotic nuclear morphology was 
assessed using Hoechst 33342 staining as 
indicated before (10,11,25,26) or by analysing 
the loss of nuclear DNA content by flow 
cytometry using propidium iodide as indicated 
elsewhere (28,29).  
Cell lysis and Western blot analysis - To 
reduce the basal levels of activity of the 
molecules analysed, mDCs (100x10
3
 cells) were 
maintained in 0.1% BSA/RPMI for 30 min 
before starting the stimulation with chemokines. 
Mature DCs were then stimulated with 
chemokines for the indicated periods of time. 
The stimulation was terminated by solubilizing 
the cells in SDS-PAGE sample buffer (100 mM 
Tris/HCl, pH 6.8, 0.05 mM sodium 
orthovanadate, 3% SDS, 1 mM EDTA, 2% 2--
mercaptoethanol, 5% glycerol) and boiled. Then 
fractionated by SDS-PAGE and transferred
 
to 
nitrocellulose membranes. After blocking with 
5% nonfat milk protein in TBST (TBS plus 0.1% 
Tween 20) pH 7.5, membranes
 
were incubated 
with the indicated antibodies in TBST and 
visualised with the appropriate HRP-conjugated 
secondary antibodies (Santa Cruz Biotecnology) 
and an ECL substrate (Pierce)
 
detection system. 
Quantification of the blots was performed using 
Multigauge software from Fujifilm.  
Immunoprecipitation- Mature DC (~50x10
6
 
DCs) were dissolved in lysis buffer A (1% NP-
40, 100 mM NaCl, 1 mM EDTA, 0.5 M of 
vanadate and 20 mM Hepes pH 7.4, including a 
protease inhibition cocktail (Sigma, Saint 
Louise)) and subjected to immunoprecipitation 
with anti-AMPKα antibody in the presence of 
TrueBlot anti-rabbit Ig agarose beads 
(TrueBlot™, eBioscience, San Diego, CA). 
Immunoprecipitates were washed 5 times in 
lysis buffer and then boiled in SDS-PAGE 
sample buffer supplemented with 50 mM 
dithiothreitol. After SDS-PAGE and transfer to 
nitrocellulose, the primary antibody step was 
followed by incubation with a horseradish 
peroxidase-conjugated antibody that recognizes 
native rabbit IgG (TrueBlot™, eBioscience, San 
Diego, CA). 
SiRNAs and nucleofections- Random control- 
and AMPK1-siRNAs were obtained from 
Santa Cruz Biotechnology. The siRNAs were 
transfected into mDCs by using nucleofection 
technology (Amaxa Biosystems) according to 
the manufacturer’s instructions. 
Proximity ligation assay (PLA). The assay was 
performed on mDC seeded onto polyornithine-
coated coverslips. The mDCs were treated with 
CCL21 and fixed in 4% PFA. Staining with 
primary antibodies was performed as in 
conventional immunofluorescence. However, 
instead of using fluorescently labeled secondary 
antibodies, a PLA was carried following 
manufacturer's instructions (30) (Duolink II in 
situ PLA detection kit, Olink Bioscience). 
Briefly, samples were incubated with secondary 
antibodies conjugated with DNA probes 
(MINUS and PLUS DNA probes). Probes were 
hybridized and ligated, followed by 
amplification of the DNA template in a rolling 
circle amplification reaction. A detection 
solution was added to identify amplified DNA. 
Finally coverslips with the cells were prepared 
using mounting medium that includes DAPI to 
stain the nuclei. The coverslips are analyzed 
with a confocal microscope and the interaction 
among ERK and AMPK proteins, detected as 
distinct fluorescent spots inside each DC, are 
subsequently quantified. 
 
Two-photon microscopy and analysis of 
apoptotic CFSE-dendritic cells in the lymph 
nodes The method has been described in detail 
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before (10,25,26,31). Briefly, CFSE-labelled 
splenic mDCs (10
8
 mDCs/ml) were dissolved in 
20 µl RPMI and injected s.c. along with LPS (1 
g/ml) into the hind footpad of recipient 
C57BL/6 mice (2x10
6
 mDCs per footpad). After 
36 h, when the mDCs have already reached the 
popliteal LNs (PLNs) (26,32), treated or control 
animals were injected intraperitoneally, 
respectively, with the AMPK activator A769662 
(3.6 mg/ 25 g mice in DMSO) or with vehicle 
control DMSO. 40.5 h after initiation of the 
experiment, the mice were injected 
intravenously with Sulforhodamine B (SR)-
FLIVO (SR, λabs 565 nm; λem >600 nm) and after 
additional 1 h the mice were sacrificed, the 
popliteal LNs extracted from the mice and 
subsequently subjected to two-photon confocal 
analysis to visualise among the injected CFSE-
mDCs those that present SR-FLIVO staining 
(see Results). Two-photon microscopy and 
analysis of apoptotic CFSE-DCs in the LNs was 
performed as described before (31). 
Statistics-Data are expressed as mean ± SD, 
and significance of differences between two 
series of results was assessed using the Student`s 
t test. Values of p<0.05 were considered 
significant and “ns”, indicates non-significant 
differences.  
 
RESULTS 
AMPK promotes apoptosis in mature dendritic 
cells in vitro. To determine if AMPK could 
regulate apoptosis in mDCs, we maintained the 
cells in complete medium in the absence or in 
the presence of the selective AMPK activators 
A769662 or AICAR. A769662 is a direct 
allosteric activator of AMPK [36]. AICAR is an 
agent that is transported into cells where is 
phosphorylated to form the AMP-mimetic S-
aminoimidazole-4-carboxamida ribonucleoside 
monophosphate (ZMP), which activates AMPK 
without altering the intracellular levels of AMP 
or ATP (33) (Fig. 1A). Western blotting analysis 
using antibodies that recognize a 
phosphorylated/active AMPK (p-AMPK 
(Thr172)), or phosphorylated acetyl coenzyme A 
carboxylase (ACC) (p-ACC (Ser 79)), which is a 
direct target of active AMPK (34), confirmed 
that the treatment of mDCs with A769662 or 
AICAR induced activation of AMPK (Fig. 
1A(a)). We treated the mDCs with the AMPK 
activators and then measured the percentage of 
apoptosis by staining the nuclei of the cells with 
Hoechst 33342. DCs treated with Akti1/2, a 
potent inhibitor of the pro-survival kinase Akt 
(10,11,25), were used as positive controls of 
apoptosis. As shown in Fig. 1A(b and c), mDCs 
treated with pharmacological activators of 
AMPK displayed increased percentage of 
apoptosis. Similar results were obtained when, 
instead of Hoechst staining, apoptosis was 
measured by analysing the loss of nuclear DNA 
content typical of apoptotic cells by flow 
cytometry using propidium iodide as label 
(28,29) (Fig. 1A(d)) or the activation of caspase-
3, another well-known apoptotic marker (Fig. 
1A(e)). When the pharmacological activators of 
AMPK were used to induce apoptosis in mDCs 
that had been pre-treated with Z-VAD-FMK, a 
general caspase inhibitor, the effects of the 
AMPK activators on the apoptosis of the cells 
were abrogated, indicating that these agents 
induce caspase-dependent cell death (Fig. 1B). 
Finally, to corroborate that AMPK played pro-
apoptotic roles in DCs, we reduced AMPK 
levels using siRNA (Fig. 1C(a)). When DCs 
with normal or reduced levels of AMPK were 
shifted to 0.1%BSA/RPMI for 24 h and then 
stained with Hoechst 33342, it was observed that 
the mDCs that displayed reduced levels of 
AMPK (Fig. 1C(b)) presented also a reduced 
percentage of apoptosis. Together the results 
indicate that AMPK can promote apoptosis in 
mDCs. 
We analysed potential mechanisms whereby 
active AMPK could induce apoptosis in DCs. 
Before we have reported that the kinase GSK3 
may induce apoptosis in DCs by promoting the 
translocation to the nucleus of the transcription 
factor FOXO (10), which controls the expression 
of the pro-apoptotic Bcl2 family member Bim 
(10,25,26,35). We tested whether similarly 
active AMPK could also promote the 
translocation of FOXO and induce 
overexpression of Bim in DCs. For this purpose, 
we transfected the DCs with FOXO1-GFP and 
then induced activation of AMPK by stimulating 
the DCs with AICAR or A769662. As shown in 
Fig 2A, these agents induced a significant 
increase in the number of DCs that displayed 
FOXO-GFP in the nucleus. Consistent with 
these results, the stimulation of DCs with 
AICAR or A769662 also caused an increase in 
Bim levels in the DCs (Fig. 2B). In similar 
experiments we did not observed any change in 
the expression of the pro-survival Bcl2 member 
Bclxl (not shown). Together these results suggest 
that AMPK could induce apoptosis in DCs by 
promoting translocation of pro-apoptotic 
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FOXO1 to the nucleus, which up-regulates the 
expression of the pro-apoptotic Bim.  
Since it has been shown that AMPK inhibits 
the kinase complex mTORC1 (36,37), and 
mTORC1 has been shown to mediate the pro-
survival signalling of the kinase Akt (38), we 
hypothesised that active AMPK may induce 
apoptosis by interfering with the pro-survival 
signalling induced from mTORC1 in DCs. To 
test this concept first, we analysed whether 
mTORC1 plays a pro-survival role in DCs. 
Inhibition mTORC1 by treating the DCs with the 
highly selective inhibitor Rapa, induces 
apoptosis, indicating that mTORC1 promotes 
survival in these cells (Fig. 2C). Next we studied 
whether CCR7 could also induce activation of 
mTORC1. As shown in Fig 2D, simulation of 
CCR7 with CCL21 induces 
phosphorylation/inhibition of the mTORC 
upstream inhibitory molecule TSC2 and an 
increase in the phosphorylation of 4EBP1, a 
direct downstream target of mTORC (Fig. 2D), 
together indicating that CCR7 induces activation 
of mTORC1. Finally, we analysed whether 
active AMPK could inhibits CCR7-dependent 
activation of mTORC1 (Fig. 2E). The treatment 
of the DCs with A769662 or AICAR which, as 
indicated by the elevated levels of 
active/phosphorylated AMPK (Thr172), induced 
activation of AMPK (Fig. 2E), also inhibited 
mTORC1 activity, as indicated by the reduction 
in the phosphorylation of 4EBP1 (Fig. 2E). 
Together the results indicate that in DCs active 
AMPK may also promote apoptosis by 
inhibiting mTORC1.  
 
Stimulation of CCR7 receptor induces 
phosphorylation / inhibition of AMPK. As we 
have shown before that stimulation of CCR7 
protects mDCs from apoptosis (10,11), we 
hypothesised that this receptor could also induce 
inhibition of pro-apoptotic AMPK in these cells. 
To test this hypothesis, the mDCs were treated 
with CCL21 for various times and then lysed in 
sample buffer. Subsequently, we examined the 
activity of AMPK using an antibody that 
recognizes the phosphorylated/inactive form of 
AMPK1p-Ser485). Stimulation with CCL21 
(Fig. 3A) or CCL19 (not shown) induced 
inactivation of AMPK, which remained at 
relatively high levels until 60 min and only 
decayed after 120 min (Fig. 3A). Consistent with 
these results, stimulation of CCR7 caused also a 
reduction of the phosphorylation of the AMPK 
substrate ACC (Fig. 3B). When we used an 
antibody that recognizes the active form of 
AMPKp-Thr172), it was observed that 
stimulation of CCR7 also led to reduced levels 
of this active form of AMPK (Fig. 3B). Finally, 
the treatments of the mDCs with compound C, a 
selective inhibitor of AMPK (24), blunted, the 
phosphorylation of the active form of AMPK (p-
Thr172) (Fig. 3C(a)), but failed to affect the 
CCR7-induced phosphorylation of Ser485 on 
AMPK (Fig. 3C(b)). Since AMPK activity is 
completely blunted after the treatment with 
compound C, the results indicate that upon 
stimulation of CCR7 the phosphorylation of 
AMPK on Ser485 was not due to an 
autophosphorylation event, but to the activity of 
an upstream kinase. In summary, the 
experiments indicate that stimulation of CCR7 in 
mDC causes phosphorylation on Ser485 and 
inhibition of AMPK, which is mediated by an 
upstream kinase. 
 
Activation of AMPK induces apoptosis of murine 
DCs in the lymph nodes. We studied whether 
active AMPK could also play a pro-apoptotic 
role in the lymph nodes (LNs), the setting where 
DCs present antigens to naïve T-cells during the 
initiation of the immune response. Before 
performing the experiment in vivo, we first 
analysed if the treatment with AMPK activators 
induced also apoptosis in the splenic mDCs in 
vitro. Treatment with AICAR and A769662 
enhanced significantly the activity of AMPK 
(Fig. 4A(a)) and the apoptosis of the cells (Fig. 
4A(b)), indicating that active AMPK is also pro-
apoptotic in splenic mDCs in culture. 
Furthermore, stimulation of splenic mDCs with 
murine CCL19 or CCL21 also induced, like in 
human mDCs, phosphorylation of AMPK on 
Ser485 (Fig. 4B).  
As it is known that conventional mDCs that 
arrive from peripheral tissues to the LNs become 
largely apoptotic in these regions (26,39), we 
studied if activators of AMPK could enhance the 
percentage of apoptotic mDCs inside the 
popliteal LNs (PLNs), which would indicate that 
active AMPK plays pro-apoptotic roles in these 
cells in vivo. For this purpose, C57BL/6 mice 
were injected subcutaneously in the hind footpad 
with carboxyflurescein diacetate succinimidyl 
ester (CFSE)-labeled splenic DCs. After 36 h, a 
time at which, as shown by us before (26), there 
is a significant number of CFSE-labeled DCs 
positioned in the PLNs, the mice were injected 
intraperitoneally with 100 moles of A769662. 
Control animals were injected with the same 
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amount of vehicle (Fig. 4C(a)). After additional 
4.5 h, the animals were injected intravenously 
with SR-FLIVO, a poly caspase binding 
inhibitor probe [(Val-Ala-Asp(OMe)-
fluoromethyl ketone (VAD-FMK)] conjugated 
to a fluorescent dye that binds irreversibly to 
apoptotic caspases and allows the detection of 
apoptotic cells in vivo (10,25,26,31). One hour 
after the injection of SR-FLIVO, the mice were 
sacrificed, the PLNs were obtained and analysed 
by two-photon microscopy. In these experiments 
it would be expected, if AMPK is pro-apoptotic, 
an enhanced SR-FLIVO staining in the mDCs in 
the PLNs obtained from the A769662-treated 
animals compared to the vehicle-treated 
controls. Consistent with this prediction, mice 
injected with A769662 displayed a significant 
increase in the percentage of SR-FLIVO-labelled 
CFSE-DCs, indicating that active AMPK plays 
pro-apoptotic roles in the mDCs in vivo (Fig. 
4C(b and c)). We also observed induction of 
apoptosis in the DCs inside the PLNs when the 
mice were injected with AICAR (not shown). In 
summary, the prior experiments indicate that 
active AMPK promotes apoptosis of mDCs both 
in vivo and in vitro. 
 
CCR7-dependent inhibition of AMPK in mDCs 
is mediated by Gi and G, but not by PI3K/Akt 
or S6K. In the next experiments we studied the 
signalling pathway that could regulate 
downstream of CCR7, the 
phosphorylation/inhibition of AMPK. As the Gi 
protein family of G proteins, and the G dimers 
associated to these proteins, mediate CCR7-
dependent survival in mDCs (10,11), we tested 
their involvement in the control of CCR7-
dependent inhibition of AMPK. Gi-mediated 
signalling was blocked by treating the mDCs 
with the selective inhibitor pertussis toxin (PTX) 
and G-mediated signalling was blocked by 
treating the cells with Gallein (40). The observed 
inhibition of the CCR7-dependent 
phosphorylation of ERK1/2 (Fig 5A(a) and (b)), 
two kinases known to be regulated by Gi and G 
(10,27), indicated that both PTX and Gallein 
blocked efficiently their targets. The treatment 
with PTX or Gallein also blunted the CCR7-
induced phosphorylation of AMPK on Ser485 
(Fig. 5A(a) and (b)), indicating that Gi and G 
regulate downstream of CCR7 the 
phosphorylation of AMPK on Ser485.  
Stimulation of CCR7 induces activation of 
Akt in mDCs (10,11,41) which is also controlled 
by the Gi family of proteins (10,11). As Akt 
mediates the phosphorylation of Ser485 on 
AMPK in a variety of cell types (18,22,23,42), 
we analysed whether it could also play a similar 
role downstream of CCR7 in mDCs. 
Surprisingly, the blocking of the activity of Akt, 
with the PI3K inhibitor LY294002 (Fig 5B(a)) 
or with the selective Akt inhibitor Akti1/2 (43) 
(Fig. 5B(b)) failed to affect CCR7-dependent 
phosphorylation of AMPK on Ser485, indicating 
that Akt does not mediate CCR7-dependent 
inhibition of AMPK in mDCs. Further 
emphasizing that Akt and AMPK are 
independently regulated, the inhibition of 
AMPK, by treating the mDCs with Compound 
C, did not affect the CCR7-dependent 
phosphorylation of Akt (not shown).  
Stimulation of CCR7 also induces activation 
of the mammalian target of rapamycin complex 
1 (mTORC1) (Fig. 5C), which promotes 
survival in mDCs (unpublished results). 
Recently, it has been shown that S6K, a 
molecule that is regulated by mTORC1 (44), 
may also directly phosphorylate AMPK on 
Ser485 (21). Therefore, we studied whether 
inhibition of S6K could block CCR7-dependent 
phosphorylation of AMPK on Ser485. To inhibit 
S6K we treated the mDCs with pharmacological 
agents that block either Akt (Akti) or mTORC1 
(Rapa or KU0063794), both upstream regulators 
of S6K (44) (Fig 5D). To analyse S6K activity 
we used an antibody that recognizes a 
phosphorylated/active form of this kinase (p-
S6K (Thr389)). Treatment of the mDCs with the 
inhibitors Akti1/2 (43), Rapamycin (43,45) and 
Ku (46), to inhibit Akt, mTORC1 and 
mTORC1/2, respectively, blunted, as expected, 
the activation of S6K. However, despite strong 
inhibition of S6K, the CCR7-dependent 
phosphorylation of AMPK on Ser485 was not 
affected (Fig. 5D). The results indicate that Akt, 
mTORC1, mTORC2 or S6K do not mediate 
CCR7-dependent inhibition of AMPK in mDCs 
(see model in Fig. 9). 
 
CCR7-dependent inhibition of AMPK in DCs is 
mediated by MEK/ERK. Upon stimulation of the 
mDCs with CCL21, we observed similar kinetics 
in the activation of the kinases MEK1/2/ERK1/2 
and phosphorylation of AMPK on Ser485 (Fig. 
6A). Therefore, we studied whether downstream 
of CCR7, MEK1/2/ERK1/2 could mediate the 
phosphorylation of AMPK on Ser485. Treatment 
of the cells with UO126 (Fig. 6B) or 
PD03255901 (Fig. 6C), two potent and selective 
inhibitors of MEK1/2 (45) and, consequently of 
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ERK1/2, the only known downstream targets of 
MEK1/2 (47), blunted CCR7-dependent 
phosphorylation of AMPK, indicating that 
MEK1/2 regulates downstream of CCR7 the 
phosphorylation of AMPK on Ser485. In the 
next experiments we studied whether ERK1/2 
could also regulate AMPK phosphorylation on 
Ser485. Our attempts to reduce the expression of 
ERK1 or ERK2 in mDC using siRNAs were 
unsuccessful. Although the siRNAs used readily 
blunted ERK1 and ERK2 expression in HL-60 
cells, we were unable to reduce the levels of 
these two kinases in mDCs (not shown). 
Therefore, we decided to use two 
pharmacological inhibitors to block ERK1/2 
activity, namely, CAY10561 (Fig. 7A) or 
FR180204 (Fig. 7B). CAY10561 displays a high 
selectivity against ERK when tested against a 
panel of 184 (48,49), and FR180 against 8 
related kinases (50). As shown in Fig. 7A and B, 
although the effects of CAY10561 and FR180 
displayed higher variability when compared to 
the effects of the MEK1/2 inhibitors; however, 
both agents blocked CCR7-dependent 
phosphorylation of AMPK1 on Ser485. 
Therefore, the results indicate that ERK1/2 can 
mediate the effects of MEK1/2 to induce 
inhibition of AMPK. As the pharmacological 
blocking of MEK1/2 and ERK1/2 prevents the 
phosphorylation/inhibition of AMPK, which 
plays pro-apoptotic roles, we predicted that 
treatment of the mDCs with the inhibitor would 
reduce the pro-survival effects induced by 
stimulation of CCR7. As shown in Fig. 7C, as 
expected, the pre-treatment of the mDCs with 
the inhibitors of MEK1/2 or ERK1/2, reduced 
the pro-survival effects induced by the 
stimulation of CCR7, although at an extent 
slightly lower than that induced by inhibition of 
Akt. 
 
ERK associates to AMPK. As downstream of 
CCR7 active MEK/ERK are required to observe 
phosphorylation of AMPK on Ser485, we 
studied the possibility that these molecules could 
associate to AMPK in mDCs. We 
immunoprecipitated the endogenous AMPKα 
from cultures of mDCs and then carried out a 
western blotting to analyze for the presence of 
ERK1 or MEK1 in the immunoprecipitates. As 
shown in the Fig. 8A, we observed that AMPKα 
and ERK1 interacted both in unstimulated or 
CCL21-stimulated mDCs, suggesting that these 
two proteins are able to associate, directly or 
indirectly, constitutively. In contrast, we did not 
detect MEK1 in the AMPK 
immunoprecipitates (not shown). Since direct or 
indirect protein-protein associations cannot be 
discriminated by immunoprecipation, to study 
whether AMPKα and ERK1 could interact 
directly each other, we performed a Proximity 
Ligation Assay (PLA) (51,52). This is a novel 
microscopy technique that allows detecting with 
high specificity and sensitivity close proximity 
between two proteins (<40 nm), suggesting 
direct interactions between these two molecules 
(30,51,52). The mDCs were plated on 
polyornithine-coated dishes, then they were 
stimulated with CCL21 and finally they were 
subjected to a PLA analysis. Negative controls 
where single antibodies against ERK1 (Fig 
8B(a)), AMPK1 (Fig 8B(a)) or MEK1 (Fig 
8B(b)) were used, showed no PLA fluorescence. 
Interestingly, we observed PLA fluorescence 
signal between the pair ERK1/AMPK only in 
CCL21-stimulated mDCs, but not in 
unstimulated mDCs, suggesting that stimulation 
of CCR7 induces proximity between these two 
kinases (Fig 8B(c)). Consistent with 
immunoprecipitation results, we did not observe 
PLA fluorescent signal between the pair 
MEK1/AMPK (not shown). Analysis of the 
interaction between ERK1 and MEK1, which 
was used as a positive control, showed also 
intense PLA fluorescence in the stimulated, but 
not in the unstimulated mDCs (Fig 8B(d)). In 
summary, the results show that ERK and AMPK 
may be part of a similar protein complex and in 
this complex active ERK may control the 
phosphorylation of AMPK on Ser485.  
 
DISCUSSION 
CCR7 directs mDCs to the LNs where the 
initiation of the immune response takes place. 
Before we have shown that in addition to 
chemotaxis, CCR7 can promote survival in 
mDCs through the kinase Akt (10-12), which 
controls survival by inducing activation of 
NFB and inhibition of FOXO1/3 and GSK3 
(10-12). To get further insights on the 
mechanisms used by CCR7 to induce survival in 
mDCs, herein we have analyzed the involvement 
of the kinase AMPK in this process. Our results 
indicate that in mDCs AMPK can play pro-
apoptotic roles in vitro and in vivo.  
The phenotypical features presented by the 
DCs that die after inducing activation of AMPK 
suggest that this kinase may induce an apoptotic 
type of death. In this regard, AMPK-dependent 
death is inhibited by the pan-caspase inhibitor z-
CCR7 promotes inhibition of AMPK in human dendritic cells 
8 
 
VAD-FMK, it associates to caspase 3 activation, 
to the fragmentation of the nucleus and to the 
increase in the expression of the pro-apoptotic 
Bcl2 family member Bim. Our results indicate 
that AMPK may promote apoptosis, at least 
partially, by inducing translocation to the 
nucleus of FOXO1, a transcription factor that 
plays pro-apoptotic roles in mDCs through the 
regulation of the expression of Bim (10,25,26), 
and by inhibiting mTORC1, a kinase complex 
controlled by CCR7 that also induces survival in 
mDCs (10,26). In other cell types AMPK has 
also been shown to be able to promote apoptosis 
using these two mechanisms (36,53,54).  
Consistent with its pro-survival role of the 
chemokine receptor CCR7 (11), we observed 
that its stimulation induces a rapid 
phosphorylation/inhibition of pro-apoptotic 
AMPK on Ser485 (18-21). This inhibition of 
AMPK may promote DC survival through the 
effects that can be exerted on FOXO and 
mTORC1. Before we showed that stimulation of 
CCR7 induces activation of Akt which, upon 
phosphorylating nuclear FOXO, induces its 
translocation to the cytoplasm (10,11), 
preventing this factor from exerting pro-
apoptotic effects through Bim. However, in 
contrast to Akt, active AMPK promotes, as 
shown above, the translocation of FOXO to the 
nucleus of DCs, from where it can regulate 
apoptosis. Thus, CCR7-mediated inhibition of 
AMPK, prevents that this kinase may oppose the 
effects of Akt on FOXO, facilitating the 
complete translocation of FOXO to the 
cytoplasm. Moreover, CCR7-dependent 
inhibition of AMPK can also prevent that this 
kinase may inhibit the pro-survival effects 
exerted by mTORC1. Thus, CCR7-mediated 
inhibition of AMPK may contribute to the 
extended survival of the DCs.  
The results suggest that downstream of CCR7 
the kinases MEK/ERK, but not Akt or S6K, 
mediates the phosphorylation of AMPK on 
Ser485. Our results also indicate that ERK and 
AMPK may be components of a signaling 
complex where active ERK controls the 
phosphorylation of AMPK on Ser485. 
Interestingly, these data contrast with prior 
results, obtained in other cells types, where it has 
been indicated that AMPK promotes inhibition 
of ERK (55-58), pointing out context dependent 
differences in the mechanism used by these two 
molecules to regulate each other. Previously it 
has also been shown that infection of PK-15 
cells with Porcine circovirus type 2 (PCV2) also 
promotes interaction between AMPK and ERK 
(58). To the best of our knowledge our work is 
the first report indicating that MEK/ERK can 
mediate the inhibition of AMPK by regulating 
Ser485 phosphorylation.  
The results obtained also indicate that 
MEK/ERK can regulate mDC survival. Until 
now we had overlooked a role for MEK/ERK as 
regulators of CCR7-dependent survival in mDCs 
probably due to the relatively less important role 
of these kinases as regulators of this function 
compared to Akt. In most early experiments, the 
effects of MEK/ERK on mDC survival were 
analysed after relatively shorts periods (6-10 h). 
Under these conditions the effects of interfering 
with MEK/ERK on survival were negligible 
when compared to that induced by Akt 
inhibition. Only when apoptosis was analysed 
after longer treatment with ERK1/2 inhibitors 
(24-40 h), MEK/ERK emerge as a regulator of 
mDC survival, although still less potent than 
Akt. In Fig 9, we present a model that 
summarizes the results obtained regarding the 
signalling mechanisms involved in the 
phosphorylation / inhibition of AMPK.  
The results indicating that MEK/ERK, but 
not Akt, control AMPK phosphorylation on 
Ser485 were unexpected for several reasons. 
First, we have shown before that Akt is a key 
mediator of CCR7-dependent survival in mDCs 
(10,11). Second, CCR7-mediated activation of 
Akt and phosphorylation of AMPK on Ser485 
were both mediated by Gi, suggesting that the 
CCR7-Gi-Akt axis may regulate the 
phosphorylation of AMPK. Third, Akt inhibits 
AMPK by directly phosphorylating Ser485 on 
AMPK in several other cell types (18,22,23,42). 
However, despite these prior results, we observe 
that inhibition of Akt or S6K, another kinase 
involved recently in the regulation of the 
phosphorylation of AMPK on Ser485 (21), 
failed to block the phosphorylation of this 
residue upon stimulation of CCR7. In contrast, 
inhibition of MEK or its direct target ERK, 
blocked CCR7-dependent phosphorylation of 
AMPK on Ser485. Therefore, MEK/ERK 
emerge as novel regulators of the 
phosphorylation/inhibition of AMPK and, 
consequently the survival of mDCs in addition to 
Akt. Interestingly MEK-ERK dependent 
phosphorylation of AMPK on Ser485, seems cell 
and/or receptor-specific because in granulosa 
cells, MEK/ERK inhibition was ineffective to 
prevent the follicle-stimulating hormone (FSH)-
mediated phosphorylation of AMPK on Ser485 
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(22). These disparate results regarding the roles 
of Akt, S6K and MEK/ERK on the 
phosphorylation of Ser485 emphasize the 
combinatorial character of the signalling 
pathways and the importance of a detailed 
knowledge of the specific pathways used by 
specific receptors in each cell type. In summary, 
the data presented herein indicate that CCR7 
may use the MEK-AMPK axis, in addition to 
Akt-dependent mechanisms (10-12), to promote 
survival in mDCs. These results add a novel 
component to the array of signals relayed from 
CCR7 to promote the survival of mDCs and 
provide new potential targets to modulate the 
function of these cells in the immune system.  
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Footnotes 
2
Abbreviations used in this paper: Acetyl coenzyme A carboxylase (ACC), mDC, mature dendritic 
cell; mTORC1 and mTORC2, mammalian target of Rapamycin complex 1 and 2; ERK1/2, 
extracellular signal related kinase1/2; PI3K, phosphoinositide 3-kinase; PTX, pertussis toxin, popliteal 
lymph node (PLN); FOXO, Forkhead box class O. 
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LEGENDS TO FIGURES 
Fig. 1. AMPK induces apoptosis in dendritic cells. A, (a) DCs were suspended in 10% FCS in 
RPMI and then incubated for 24 h either in this medium alone (-) or in this medium plus Akt 
inhibitor (Akti) (5 M), AICAR (1 mM) or A769662 (25 M). Aliquots of DCs were subjected to a 
Western blotting analysis with Abs against phospho-AMPK (T172), phospho-ACC or total 
AMPK. (b) Photographs taken from representative samples of the Hoechst 33342 stained DCs 
treated as in (a). Arrowheads indicate apoptotic cells, showing condensed or fragmented nuclei. (c) 
DCs were suspended in 10% FCS in RPMI and then incubated in medium alone (-) or in medium 
plus Akt inhibitor (Akti), AICAR or A769662, as in (a). The number represents fold-increase in the 
number of apoptotic DCs, determined by Hoechst 33342 staining, with respect to the control un-
treated DCs kept in 10% FCS in RPMI, which was considered as 1. Results shown represent the 
mean±SD (n=4). (d) The cells were treated or not with Akti, AICAR or A769662 as in (b). The 
number represents fold-increase in the number of DCs that presented DC fragmentation upon 
propidium iodide (PI) staining with respect to control un-treated DCs kept in 10% FCS in RPMI. 
Results shown represent the mean±SD (n=6). (e) The DCs were suspended in 10% FCS in RPMI 
and then incubated for 33 h either in this medium alone (-) or in this medium plus Akt inhibitor 
(Akti), AICAR or A769662 as in (a). Aliquots of DCs were subjected to a Western blotting analysis 
with an antibody against caspase-3. The blots were probed with an antibody against -tubulin to 
show equal loading. A representative experiment out of two performed is shown. B, DCs were 
suspended in 0.1% BSA in RPMI and then incubated for 40 h either in this medium alone (-) or 
including AICAR (1 mM) or A769662 (25 M), either in the absence (control) or in the presence of 
10 g/ml of pan caspase inhibitor z-VAD-FMK. The apoptotic DCs observed in medium alone (-) 
untreated with z-VAD-FMK were given an arbitrary value of 1 and the fold-increase of apoptosis in 
the other samples were referred to this value. Results shown represent the mean±SD (n=5). C, 
mDCs were nucleofected either with random siRNA (Control-siRNA) or with a siRNA specific for 
AMPK (AMPK1-siRNA). (a). 36 h after nucleofection, mDCs were washed in RPMI and then an 
equal number of live DCs, determined by trypan blue exclusion, were subjected to a Western 
blotting with an anti-AMPK antibody. To confirm equal loading, the blots were reprobed with an 
antibody reacting with -actin. (b). Samples of DCs nucleofected either with Control or with 
AMPK1-siRNA were washed in RPMI and then an equal number of live DCs, determined by 
trypan blue exclusion, were transferred to 0.1% BSA in RPMI for additional 24 h. At the end of this 
period, the DCs were stained with Hoechst. The number of apoptotic DCs observed in the Control 
siRNA nucleofected DCs were given an arbitrary value of 1, and the number of apoptotic DCs 
observed in AMPK-siRNA transfected DCs were referred to this value. Results shown represent the 
mean±SD (n=3).  
 
Fig. 2. Active AMPK may promote apoptosis by inducing translocation of FOXO1 to the 
nucleus and by inhibiting mTORC1. A, (a) The DCs were transfected with vector- or FOXO1-
GFP and 6 h after transfection, the cells were re-suspended in 10%FCS RPMI and then either kept 
untreated (control) or treated with AICAR (1 mM), A769662 (25 M) or LY294002 (100 M) for 
additional 2.5 h. Subsequently, the DCs were plated onto polyornithine-coated (PON)-coated 
coverslips, fixed, permeabilized and stained with Hoechst 33342. The DCs were examined with a 
fluorescence microscope. Scale bar represents 20 m. (b) Bar diagram representing the percentage 
of vector- or FOXO1-GFP transfected DCs with GFP staining concentrated in the nucleus. Results 
shown represent the mean±SD (n=3).  
B, DCs were suspended in 0.1% BSA in RPMI and then kept untreated (-) or stimulated with 
A769662 (25 M) or AICAR (1 mM) for 16 h. Aliquots of the DCs were subjected to a Western 
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blot with an Ab against Bim. Blots were reprobed with an antibody reacting with -actin to show 
equal loading (a representative experiments is shown). C, (a) The DCs were suspended in 0.1%BSA 
in RPMI and then treated (+) or not (-) for 40 h with Rapamycin (RAPA, 100 nM). DCs maintained 
in 10%FCS in RPMI were used as negative controls. The DCs were plated on PON-coated 
coverslips, fixed, stained with Hoechst and the apoptotic cells examined as indicated in Methods 
(see article). Results shown represent the mean±SD (n=3). (b) To confirm that RAPA inhibited 
mTORC1, aliquots of the control- or RAPA-treated DCs from (a), were stimulated (+) or not (-) 
with CCL21 (15 nM). Subsequently, the DCs were lysed and analyzed by SDS-PAGE, followed by 
Western blotting. The blots were analyzed with Abs against phosphorylated-4EBP1 (T37/46), 
phosphorylated-Akt (S473). To show equal loading, the membranes were reprobed with an Ab 
against Akt D, DCs (100,000 cells), suspended in 0.1% BSA in RPMI, were stimulated for the 
indicated times with CCL21 (15 nM), then lysed and analyzed by SDS-PAGE, followed by Western 
blotting with Abs against phosphorylated TSC2T1462) and phosphorylated 4EBP1 (T37/46). To 
show equal loading, the membranes were reprobed with Abs against total 4EBP1. A representative 
experiment out of 3 performed is shown. E, The DCs were suspended in 0.1% BSA in RPMI and 
then kept untreated (Control) or treated with A769662 (25 M) or AICAR (1 mM) for 60 min. 
Subsequently, the DCs were stimulated (+) or not (-) with CCL21 (15 nM), then lysed and analyzed 
by SDS-PAGE, followed by Western blotting. The blots were analyzed with Abs against 
phosphorylated-4EBP1 (T37/46), phosphorylated-AMPK (T172). To show equal loading, the 
membranes were reprobed with an Ab against AMPK. 
 
Fig. 3. Stimulation of CCR7 induces phosphorylation/inhibition of AMPK. A, DCs (100,000 
cells), suspended in 0.1% BSA in RPMI, were stimulated for the indicated times with CCL21 (15 
nM), then lysed and analyzed by SDS-PAGE, followed by Western blotting with Abs against 
phosphorylated/inhibited AMPK1S485). To show equal loading, the membranes were reprobed 
with Abs against total AMPK. A representative experiment out of 3 performed is shown. B, DCs 
(100,000 cells), suspended as in (A), were stimulated with CCL21 for the indicated times and then 
extracted and subjected to a Western blotting with Ab against phospho-ACC (S79) and against 
phosphorylated/active AMPK (T172). To show equal loading the membrane was reprobed with an 
Ab against total AMPK. A representative experiment out of 3 performed is shown. C, (a) DCs, 
suspended as in (A), were either untreated (Control) or treated with AMPK inhibitor Compound C 
(20 M) for 60 min. Control and Compound C-treated DCs were stimulated with CCL21 (15 nM) 
for 5 min, and subsequently, lysed and subjected to Western blot analysis with Abs against phospho-
AMPK (T172) and AMPK. A representative experiment out of 3 performed is shown. (b) 
Aliquots of the Control or Compound C-treated samples, stimulated or not with CCL21, were used 
to analyze the activity of AMPK using the anti-phosphorylated AMPK (S485) antibody. To show 
equal loading the membrane was reprobed with an Ab against total AMPK.  
 
Fig. 4. Activation of AMPK increases the apoptosis of dendritic cells in vitro and in the lymph 
nodes. A, (a) Splenic mDCs (500,000 cells) suspended in 10%FCS in RPMI were kept unstimulated 
(control) or stimulated for the indicated times with AICAR (1 mM) or A769662 (25 M), then lysed 
and analyzed by SDS-PAGE, followed by Western blotting with Abs against phospho-AMPK 
T172), total AMPKand-actin.. A representative experiment out of 5 performed is shown. (b) 
Aliquots of the Splenic DCs treated as in (a) for 2 h were fixed and stained with Hoechst 33342 to 
detect apoptotic DCs. The number represents the fold-increase in the number of apoptotic DCs 
respect to the number of apoptotic DCs observed in the controls that was considered as 1. Results 
represent the mean±SD (n = 6 experiments). B, Splenic DCs (500,000 cells) suspended in 0.1% 
BSA in RPMI were stimulated for the indicated times with murine CCL19 or CCL21 (both at 15 
nM), then lysed and analyzed by SDS-PAGE, followed by Western blotting with Abs against 
phospho-AMPKS485), total AMPKand-actin. A representative experiment out of 5 
performed is shown. C, (a) Experimental protocol. 2x10
6 
CFSE-labeled splenic DCs were injected 
in the footpads of recipient mice. After 36 h, the animals were injected intraperitoneally with 100 
moles of A769662 or a similar volume of vehicle DMSO. After additional 4.5 h, mice were 
injected (i.v) with SR-FLIVO to stain apoptotic DCs in the LNs. After 1h, the popliteal LNs were 
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extracted, fixed and subjected to two-photon analysis. (b) Representative SR-FLIVO staining 
displayed by CFSE-labeled DCs obtained from the LNs of animals treated either with A769662 or 
DMSO. The LNs of the mice were extracted and studied by two-photon microscopy as indicated in 
Methods. (c) The stacks of optical images of the LNs were examined with the Leica Confocal 
Software and the values of the Maximum Amplitude of the SR-FLIVO and CFSE channel were 
obtained as indicated before (see Methods). Data from 2 experiments are presented. The data are 
represented as maximum intensity of SR-FLIVO over maximum intensity of CFSE for each 
individual DC in a LN. A769662-treated animals, (74 DCs, Exp 1, 26 DCs Exp 2), DMSO vehicle-
treated animals (171 DCs, Exp 1, 237 DCs. Exp 2).  
 
Fig. 5. Signaling downstream of CCR7 regulating the phosphorylation of AMPKon Serine 
485 A, (a) DCs (100,000 cells) in complete medium were either kept untreated (Control) or treated 
with Pertussis toxin (PTX) (100 ng/ml) for 180 min. Subsequently, the DCs were washed and 
suspended in 0.1% BSA in RPMI. Control- and PTX-treated DCs were stimulated with CCL21 (15 
nM) for 5 min and subsequently lysed and subjected to Western blotting with the Ab against 
phosphorylated-AMPK (S485) or phosphorylated-ERK1/2 (T202/Y204 ERK1/ T185/Y187 
ERK2). ERK2 levels show equal loading of the gels.A representative experiment out of 3 performed 
is shown. (b) DCs, untreated or pretreated with the G inhibitor Gallein (40) for 15 min, were 
stimulated or not with CCL21 for 5 min, then lysed and aliquots subjected to Western blot with an 
Ab against phosphorylated AMPK1 (S485) and phosphorylated-ERK1/2 as in (a). ERK2 levels 
show equal loading of the gels. A representative experiment out of 3 performed is shown. B, DCs 
suspended in 0.1% BSA in RPMI were either left untreated (Control) or pre-treated for 60 min with 
(a) the PI3K inhibitor LY294002 (100 M, 60 min) or (b) the Akt inhibitor Akti, 1,2 (5 µM). The 
DCs were subsequently stimulated or not with CCL21 (15 nM) for 5 min and then lysed and aliquots 
subjected to Western blot with the Ab against phosphorylated/inhibited AMPK1 (S485) or against 
phosphorylated/active Akt1 (S473). -actin levels show equal loading of the gels. A representative 
experiment out of 3 performed is shown. C, DCs (100,000 cells), suspended in 0.1% BSA in RPMI, 
were stimulated for the indicated times with CCL21 (15 nM), then lysed and analyzed by SDS-
PAGE, followed by Western blotting with Abs against phosphorylated-TSC2T1462), 
phosphorylated-mTOR (S2448) or phosphorylated-4EBP1(T37/46). To show equal loading, the 
membranes were reprobed with Abs against total TSC2 and mTOR. D, DCs suspended in 0.1% 
BSA in RPMI were either left untreated (control) or pre-treated for 60 min with Akt inhibitor (Akti) 
(5 M), RAPA (100 nM) or KU0063794 (Ku) (500 nM). The DCs were subsequently stimulated or 
not with CCL21 (15 nM) for 5 min. The DCs were then lysed and analyzed by Western blotting with 
Abs against phosphorylated/inactive AMPK1 (S485), against phosphorylated/active S6K (T389) 
and phosphorylated/active Akt (S473). Membranes were also probed with antibodies that recognize 
total S6K and AMPK.  
 
Fig. 6. CCR7-dependent phosphorylation/inhibition of AMPK is mediated by MEK. A, DCs 
(100,000 cells) suspended in 0.1% BSA in RPMI were stimulated for the indicated times with 
CCL21 (15 nM), then lysed and analyzed by SDS-PAGE, followed by Western blotting with Abs 
against phosphorylated AMPK1S485), MEK1/2 (S217/221), ERK1/2 (T202/Y204 ERK1/ 
T185/Y187 ERK2) To show equal loading, the membranes were reprobed with an Ab against 
AMPK. A representative experiment out of 3 performed is shown. B, (a) DCs suspended in 0.1% 
BSA in RPMI were either left untreated (Control) or pre-treated with UO126 (2.5 µM, 60 min). The 
mDCs were subsequently stimulated or not with CCL21 for 5 min and then lysed and the aliquots 
subjected to Western blot with an antibody against phosphorylated/inactive AMPK1 (S485) or  
phosphorylated-active ERK1/2 (T202/Y204 ERK1 / T185/Y187 ERK2). -tubulin (-TUB) levels 
show equal loading of the gels. A representative experiment out of 3 performed is shown. (b) Fold-
increase in the phosphorylation of AMPK in control and UO126 (UO)-treated mDCs, upon 
stimulation with CCL21. In both control and UO126 treated DCs the degree of phosphorylation of 
the unstimulated DCs was given an arbitrary value of 1 and fold increase in the CCL21-stimulated 
mDCs was represented. (c) Similar to (b) with the difference that Fold increase-in phosphorylation 
of ERK1/2 was examined. C, (a) The experiments were performed as described in (B), with the only 
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difference that the DCs were treated with PD325901 (1 µM, 60 min). (b) and (c), similar to (b) and 
(c) in (B), with the only difference that PD325901 was used. 
 
Fig. 7. CCR7-dependent phosphorylation/inhibition of AMPK is mediated by ERK. A, (a) DCs 
suspended in 0.1% BSA in RPMI were either left untreated (Control) or pre-treated with CAY10561 
(20 µM, 2,5 h). The DCs were stimulated with CCL21 (15 nM) for 5 min and then lysed and 
aliquots subjected to Western blot with antibodies against phosphorylated/inactive AMPK1 
(S485), total AMPK, phosphorylated-active ERK1/2 (T202/Y204 ERK1 / T185/Y187 ERK2) and 
total ERK2.. A representative experiment out of 5 performed is shown. (b) Fold-increase in AMPK 
phosphorylation in control and CAY10561-treated mDCs, upon stimulation with CCL21. In both 
control and CAY10561-treated DCs the degree of phosphorylation of the unstimulated DCs were 
given an arbitrary value of 1 and the fold increase in the CCL21-stimulated mDCs was represented. 
(c) Similar to (b) with the difference that Fold increase-in phosphorylation of Erk1/2 was examined. 
In (b) and (c), the results represent the mean±SD (n = 5 experiments). B, (a) Experiments were 
performed as described in (A), with the differences that FR180 (100 µM, 60 min) was used and that 
anti-total ERK1/2 shows equal loading of the gels. A representative experiment out of 3 performed 
is shown. (b) Similar to A(b), with the difference that fold-increase in AMPK phosphorylation was 
examined in the presence of FR180 as indicated in B(a). (c) Experiments similar to A(c) with the 
difference that fold-increase in phosphorylation of Erk1/2 was examined in the presence of FR180 
as indicated in B(a). In (b) and (c), the results represent the mean±SD (n = 3 experiments). C, 
Relative number of apoptotic DCs in unstimulated (-) and CCL21-stimulated DCs (+), after treating 
the mDCs with Akt inhibitor (Akti), the MEK1/2 inhibitor UO126 (UO) and the ERK1/2 inhibitor 
CAY10561 (CAY). Results represent the mean±SD (n = 5 experiments). 
 
Fig. 8. AMPK interacts with ERK1. A, Equal number of DCs, stimulated (+) or not (-) with 
CCL21 (15 nM), were subjected to immunoprecipitation with anti-AMPK antibody orwith IgG 
control and subsequently the immunoprecipates were separated by SDS-PAGE, followed by 
Western blotting with anti-ERK1 or anti-AMPKantibodies. A lysate of DCs was used as positive 
control. Aliquots of the lysates used to immunoprecipitate AMPK were analyzed for Western 
blotting for the presence of -actin to demonstrate equal amount of proteins immunoprecipitated 
(not shown). B, Interaction between ERK1 and AMPK in mDCs was detected as fluorescent 
signals using the proximity ligation assay (PLA). (a) and (b) PLA negative controls performed by 
labeling the DCs only with (a) the anti-ERK1 or anti-AMPK antibodies plus the anti-rabbit 
MINUS and the anti-Goat PLUS and (b) the anti-MEK1 antibody and the anti-rabbit MINUS and 
the anti-mouse PLUS probes. Normarski and nuclei stained with Hoechst 33342 are also shown. 
(Scale bar, 10 μm). In (a) and (b) the number of fluorescent signals per cell was also quantified. At 
least 40 cells per field were counted. Results represent the mean±SD (n = 3 experiments). (c) PLA 
fluorescent staining, indicating interaction between ERK1 and AMPK after CCL21 stimulation. 
(d) Positive control. PLA fluorescent staining between MEK1 and ERK1 upon CCL21 stimulation. 
Normarski and nuclei stained with Hoechst 33342 are also shown. (Scale bar, 10 μm). In (c) and (d) 
the number of fluorescent signals per cell was also quantified. At least 40 cells per field were 
counted. Results represent the mean±SD (n = 3 experiments). 
 
Fig. 9. CCR7-stimulated phosphorylation-inhibition of AMPK. Stimulation of CCR7 with 
CCL19 or CCL21 induces Gi, G mediated activation of the kinases MEK1/2 / ERK1/2. CCR7 also 
induces activation of the PI3K/Akt/mTORC1/4EBP1 and S6K pathway, which promote survival in 
mDCs. Active AMPK induces apoptosis in mDCs by inhibiting the pro-survival effects of mTORC1 
and by promoting translocation of the transcription factor FOXO to the nucleus, where it can control 
the expression of the pro-apoptotic Bcl2 family member Bim. Stimulation of CCR7 regulates, 
through the Gi,G/MEK1/2-ERK1/2 pathway (and independently of the 
PI3K/Akt/mTORC1pathway), the phosphorylation of the kinase AMPK on S485, which results in 
the inhibition of this kinase and the consequently dampening of its pro-apoptotic effects. Therefore, 
CCR7 promotes survival in DCs through Akt-dependent mechanisms described before and by 
promoting MEK/ERK dependent inhibition of AMPK.  
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